We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Giemsa Stain Outperforms Urease Test for Helicobacter Pylori Diagnosis

By LabMedica International staff writers
Posted on 05 May 2020
Print article
Image: The positive results of Helicobacter pylori infection by the traditional Giemsa stain. White arrows indicate stained Helicobacter pylori (blue) that are attached to the brush border of the gastric foveolar epithelial cells (Photo courtesy of National Health Research Institutes).
Image: The positive results of Helicobacter pylori infection by the traditional Giemsa stain. White arrows indicate stained Helicobacter pylori (blue) that are attached to the brush border of the gastric foveolar epithelial cells (Photo courtesy of National Health Research Institutes).
More than 50% of the worldwide population is infected by Helicobacter pylori which is harbored in their upper gastrointestinal tract. Despite having chronic gastritis, most people infected by H. pylori are asymptomatic and have no specific clinical signs and symptoms.

Giemsa stain and rapid urease test (CLO test) are the most performed tests of H. pylori infection at first‐line clinical examination because of their simplicity and reliability. However, the sensitivity of CLO test is significantly reduced in patients with atrophic gastritis and intestinal metaplasia, and the disadvantages of Giemsa stain are higher cost and time‐consuming.

Medical scientists at the Taiwanese National Health Research Institutes (Zhunan, Taiwan) collected and retrieved tissue specimens of 233 patients with gastritis or/and gastric ulcer from diagnostic resection specimens. Tissue specimens of gastric mucosa were separated into three parts for the traditional Giemsa stain, modified Giemsa stain, and CLO test. For the CLO test (Kimberly‐Clark, Irving TX, USA), 2‐3 mm specimen was placed into medium containing urea and examined.

The scientists reported that the modified Giemsa stain was comparable to the traditional one. Statistical analysis indicated that the modified Giemsa stain obtains greater accuracy in H. pylori‐infected patients with gastritis and ulcer than the CLO test (48.1% versus 43.7%). Moreover, considering the prognosis of different symptoms of gastric diseases, the modified Giemsa stain has a more accurate prognosis than combination symptoms. Seventy‐seven of the 173 gastritis patients (44.5%) were diagnosed as positive for H. pylori infection and 96 (55.5%) as negative by the modified Giemsa stain.

The authors concluded that the modified Giemsa stain was more simplified and time‐saving than traditional Giemsa stain, which is comparable to the traditional one and was confirmed to be better than CLO test using 233 H. pylori‐infected patients with gastric disease. In clinical examination, this modified Giemsa stain can be applied to routine examination and provides quick and accurate diagnosis and prognosis to H. pylori‐infected patients with gastric diseases. The study was published in the April, 2020 issue of the Journal of Clinical Laboratory Analysis.

Related Links:
Taiwanese National Health Research Institutes
Kimberly‐Clark


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.